ConductScience.org, home

Paper24045166

Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.

Kmiecik J and 7 others. J Neuroimmunol, 2013. Cited by 334 papers, by iCite.

Cite this record

ConductScience Library. Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. Papers, record 24045166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24045166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level.
PubMed
Journal
J Neuroimmunol
PubMed
Year
2013
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
334
iCite
Relative citation ratio, by iCite
9.01
iCite
Revised in PubMed
2022-04-08
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kmiecik JJustyna
2Poli AAurélie
3Brons NHNicolaas H C
4Waha AAndreas
5Eide GEGeir Egil
6Enger PØPer Øyvind
7Zimmer JJacques
8Chekenya MMartha

Source PubMed

Download CSV of authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Brain NeoplasmsMajor topic
CD28 AntigensMajor topic
CD3 ComplexMajor topic
GlioblastomaMajor topic
Lymphocytes, Tumor-InfiltratingMajor topic
Adolescent
Adult
Aged
Aged, 80 and over
Antigens, CD
CTLA-4 Antigen
Child
Female
Follow-Up Studies
Forkhead Transcription Factors
Humans
Immunosuppressive Agents
Kaplan-Meier Estimate
Macrophages
Male
Microglia
Middle Aged
Young Adult

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT05106725Wearable Devices and Biomarkers Project (Healthiomics)BackgroundClinicalTrials.gov
NCT05831631Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain TumorsBackgroundClinicalTrials.gov

Download CSV of trials

Cited by274

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 334 citations.

PMIDTitleJournalYearIn PapersSource
42619051The Imbalance Between Tumor Immunosurveillance and Tumor Immune Escape in Glioblastoma.Immunol Cell Biol2026https://conductscience.org/library/papers/42619051PubMed
42375809Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances.Mil Med Res2026https://conductscience.org/library/papers/42375809PubMed
42062602Histopathological, immunohistochemical, and molecular characterization of Coenurus cerebralis infection in sheep with evaluation of cerebrospinal cytokine responses.Parasitol Res2026https://conductscience.org/library/papers/42062602PubMed
41929521Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.Front Immunol2026https://conductscience.org/library/papers/41929521PubMed
41789657Cellular and inflammatory characteristics of patient‑derived glioblastoma organoids during in vitro cultivation.Oncol Rep2026https://conductscience.org/library/papers/41789657PubMed
41652635Precision oncology in a dish: patient-derived glioma organoids to guide novel therapeutic strategies.Biomark Res2026https://conductscience.org/library/papers/41652635PubMed
41507535Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity.Nat Cancer2026https://conductscience.org/library/papers/41507535PubMed
41268299Brain microenvironment orchestrates highly aggressive tumor variants: current trends and therapeutic approaches.Front Aging Neurosci2025https://conductscience.org/library/papers/41268299PubMed
41105161T cell immunity in glioma and potential implications for immunotherapy: A systematic review.Neuro Oncol2026https://conductscience.org/library/papers/41105161PubMed
41053233The promise of immunotherapy for central nervous system tumours.Nat Rev Immunol2026https://conductscience.org/library/papers/41053233PubMed
41001043Development of a novel prognostic model for mantle cell lymphoma based on quantitative detection of CD3 by quantitative dot blot.Front Oncol2025https://conductscience.org/library/papers/41001043PubMed
40933033The glioma microenvironment and its impact on antitumor immunity.Neurooncol Adv2025https://conductscience.org/library/papers/40933033PubMed
40867165Unraveling Glioblastoma Heterogeneity: Advancing Immunological Insights and Therapeutic Innovations.Brain Sci2025https://conductscience.org/library/papers/40867165PubMed
40596223Single-dose radiotherapy is more effective than fractionation when combined with anti-PD-1 immunotherapy in glioblastoma.Sci Rep2025https://conductscience.org/library/papers/40596223PubMed
40591036Carboxypeptidase Q(CPQ) promotes glioma progression by inducing M2 macrophage polarization and immunosuppression.Discov Oncol2025https://conductscience.org/library/papers/40591036PubMed
40524972Evaluating the Diagnostic and Prognostic Value of Peripheral Immune Markers in Glioma Patients: A Prospective Multi-Institutional Cohort Study of 1282 Patients.J Inflamm Res2025https://conductscience.org/library/papers/40524972PubMed
40361496Reduced HLA-I Transcript Levels and Increased Abundance of a CD56dim NK Cell Signature Are Associated with Improved Survival in Lower-Grade Gliomas.Cancers (Basel)2025https://conductscience.org/library/papers/40361496PubMed
40265144Blood-Based Prognostic Prediction Model for Glioblastoma: Construction and Validation.Cancer Manag Res2025https://conductscience.org/library/papers/40265144PubMed
40236954Rat Sarcoma (RAS)-Protein-Targeting Synthetic Cell-Penetrating Peptide as an Anticancer Biomaterial.Biomater Res2025https://conductscience.org/library/papers/40236954PubMed
40215269Single-cell dissection of the genotype-immunophenotype relationship in glioblastoma.Brain2025https://conductscience.org/library/papers/40215269PubMed

See all 274 cited byDownload CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/24045166

GET https://conductscience.org/api/papers/v1/24045166/cited_by?page=2